Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine response stratification in treatment-resistant depression
NL-OMON56574Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of esketamine in treatment-resistant depression (TRD) and major depressive disorder (MDD), sponsored by Radboud University Medical Center. Primary endpoints: Change in MADRS score at 4 weeks, Change in BOLD signal and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON56574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56574.